miRNA
MiRxes Launches HK$880.5M IPO on Hong Kong Stock Exchange
The Singaporean company said it will use the proceeds to support commercialization of its gastric cancer test, further assay development, and other business purposes.
Craif Raises $22M in Series C Round to Expand US, Japan Operations
The Nagoya University spinout will open an office in San Diego and is working toward FDA approval of its miSignal early cancer detection test.
AccuStem Sciences to Access Samples From Italian Trial to Validate Lung Cancer Screening Test
The firm is gearing up to launch its microRNA-based assay in the US in 2026 and hopes that data from the trial will help to demonstrate its added value.
Mirxes Gets $40M Financing From CBC Group's R-Bridge to Support Global Expansion
The company is developing blood-based microRNA tests for early cancer detection and screening, with its flagship assay, GastroClear, already approved as an IVD in Singapore.
The company hopes to attract investors to fund its next steps after publishing early data from a training and validation study using public miRNA data.